Read by QxMD icon Read

Cardiovascular Diabetology

Andrea Maria Maresca, Luigina Guasti, Sara Bozzini, Christian Mongiardi, Nicolò Tandurella, Rossana Corso, Francesco G Zerba, Alessandro Squizzato, Leonardo Campiotti, Francesco Dentali, Catherine Klersy, Anna M Grandi, Colomba Falcone
BACKGROUND: Soluble Receptor for Advanced Glycation End Products (sRAGE) may be considered a marker inversely related to inflammation and its participation has been established in patients with advanced atherosclerotic vascular diseases. However, it is still unknown whether sRAGE reduction could be early metabolic change in the first stage of hypertension and initial hypertension-associated cardiac damage. We sought to determine the sRAGE values in otherwise healthy, untreated and recently diagnosed mild hypertensives and evaluate their association with blood pressure (BP) values, metabolic parameters, and with subclinical initial signs of cardiac target organ damage (TOD)...
February 12, 2019: Cardiovascular Diabetology
Damilola D Adingupu, Sven O Göpel, Julia Grönros, Margareta Behrendt, Matus Sotak, Tasso Miliotis, Ulrika Dahlqvist, Li-Ming Gan, Ann-Cathrine Jönsson-Rylander
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In clinical studies it has been shown that SGLT2i's promote a general shift to fasting state metabolism characterized by reduced body weight and blood glucose, increase in glucagon/insulin ratio and modest increase in blood ketone levels. Therefore, we investigated the connection between metabolic changes and cardiovascular function in the ob/ob-/- mice; a rodent model of early diabetes with specific focus on coronary microvascular function...
February 7, 2019: Cardiovascular Diabetology
Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li, Xiaochen Yu, Bei Sun, Liming Chen
BACKGROUND: Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reported to improve glycaemic control in patients with type 2 diabetes in an insulin-independent manner. The aim of this study was to investigate the effect of empagliflozin on myocardium injury and the potential mechanism in type 2 diabetic KK-Ay mice. METHODS: Thirty diabetic KK-Ay mice were administered empagliflozin (10 mg/kg/day) by oral gavage daily for 8 weeks...
February 2, 2019: Cardiovascular Diabetology
Rongzhong Huang, Kerry Mills, Julio Romero, Yan Li, Zicheng Hu, Yu Cao, Hua Huang, Yu Xu, Lihong Jiang
BACKGROUND: Carotid artery intima-media thickness (cIMT) progression is a surrogate marker of atherosclerosis with a high predictive value for future CVD risk. This study evaluates the comparative efficacies of lipid lowering, hypoglycemic, antihypertensive and antiplatelet medications on cIMT progression. METHODS: We conducted a network meta-analysis (NMA) to evaluate the relative efficacies of several drug classes in modifying cIMT progression. After a literature search in several electronic databases, studies were selected by following predetermined eligibility criteria...
January 30, 2019: Cardiovascular Diabetology
Shruti Rawal, Prashanth Thevakar Nagesh, Sean Coffey, Isabelle Van Hout, Ivor F Galvin, Richard W Bunton, Philip Davis, Michael J A Williams, Rajesh Katare
BACKGROUND: The diabetic heart undergoes remodelling contributing to an increased incidence of heart failure in individuals with diabetes at a later stage. The molecular regulators that drive this process in the diabetic heart are still unknown. METHODS: Real-time (RT) PCR analysis was performed to determine the expression of cardiac specific microRNA-208a in right atrial appendage (RAA) and left ventricular (LV) biopsy tissues collected from diabetic and non-diabetic patients undergoing coronary artery bypass graft surgery...
January 29, 2019: Cardiovascular Diabetology
Zheng Qin, Kuo Zhou, Yue-Ping Li, Jian-Long Wang, Wan-Jun Cheng, Cheng-Ping Hu, Chao Shi, Hua He, Yu-Jie Zhou
BACKGROUND: Increasing evidence has suggested that the presence of remnant lipoproteins is a significant risk factor for atherosclerosis. Remnant lipoproteins are lipoproteins that are rich in triglycerides (TGs), and the main components include very-low-density lipoprotein (VLDL) in the fasting state. Diabetic patients often have hypertriglyceridemia with elevated levels of VLDL cholesterol but normal levels of low-density lipoprotein cholesterol (LDL-C). The aim of the present study was to elucidate the potential role of remnant lipoproteins-induced atherosclerosis in the occurrence and development of in-stent restenosis (ISR) in diabetic patients with coronary artery disease...
January 28, 2019: Cardiovascular Diabetology
Sho-Ichi Yamagishi
Atrial fibrillation (AF) is one of the most common arrhythmias in elderly people. The risk of thromboembolic stroke is increased in AF patients, especially those with diabetes. Anticoagulant therapy, such as warfarin and non-vitamin K oral anticoagulants (NOACs), is recommended for diabetic patients with AF. However, recent guidelines do not preferentially recommend NOACs over warfarin for diabetic patients. Variability of glycemic control in diabetic patients could affect the pharmacokinetics and anticoagulant activity of warfarin, therefore, the risk-benefit balance of warfarin is prone to be compromised in diabetic patients with AF...
January 28, 2019: Cardiovascular Diabetology
Katharina Fritzen, Oliver Schnell
Novel studies have increased our knowledge regarding optimal treatment options in diabetes. Key studies that have broadened our knowledge about optimal treatment options in diabetes in recent years are cardiovascular outcome trials (CVOTs) and studies investigating aspects of digitalisation and monitoring of glucose (e.g. PDM-ProValue). We aimed at highlighting similarities between the two important pillars for a successful diabetes management. We emphasise the need for a consideration of both approaches in future clinical trial designs and protocols...
January 28, 2019: Cardiovascular Diabetology
Kolade Oluwagbemigun, Anette E Buyken, Ute Alexy, Matthias Schmid, Christian Herder, Ute Nöthlings
BACKGROUND: Reports on body mass index (BMI) trajectories from childhood into late adolescence, their determinants, and subsequent cardiometabolic risk markers, particularly among European populations have been few. Moreover, sex-specific investigation is necessary considering the sex difference in BMI, and the sex-specific association between BMI and some cardiometabolic risk markers. METHODS: Using a sample from the DOrtmund Nutritional and Anthropometric Longitudinally Designed study, we explored sex-specific trajectories of the BMI standard deviation score (SDS) from 4 to 18 years of age in 354 males and 335 females by latent (class) growth models...
January 19, 2019: Cardiovascular Diabetology
Zhongwei Yin, Yanru Zhao, Mengying He, Huaping Li, Jiahui Fan, Xiang Nie, Mengwen Yan, Chen Chen, Dao Wen Wang
BACKGROUND: Metabolic abnormalities have been implicated as a causal event in diabetic cardiomyopathy (DCM). However, the mechanisms underlying cardiac metabolic disorder in DCM were not fully understood. RESULTS: Db/db mice, palmitate treated H9c2 cells and primary neonatal rat cardiomyocytes were employed in the current study. Microarray data analysis revealed that PGC-1β may play an important role in DCM. Downregulation of PGC-1β relieved palmitate induced cardiac metabolism shift to fatty acids use and relevant lipotoxicity in vitro...
January 11, 2019: Cardiovascular Diabetology
Shiyun Wang, Jie Wang, Rong Zhang, Aihua Zhao, Xiaojiao Zheng, Dandan Yan, Feng Jiang, Wei Jia, Cheng Hu, Weiping Jia
BACKGROUND: Serum haptoglobin (Hp) has been closely associated with cardio-cerebrovascular diseases. We investigated a metabolic profile associated with circulating Hp and carotid arterial functions via a targeted metabolomics approach to provide insight into potential mechanisms. METHODS: A total of 240 participants, including 120 patients with type 2 diabetes mellitus (T2DM) and 120 non-diabetes mellitus (non-DM) subjects were recruited in this study. Targeted metabolic profiles of serum metabolites were determined using an AbsoluteIDQ™ p180 Kit (BIOCRATES Life Sciences AG, Innsbruck, Austria)...
January 11, 2019: Cardiovascular Diabetology
Kassem Sharif, Suheil Ghadir, Daniela Jakubowicz, Howard Amital, Nicola Luigi Bragazzi, Abdulla Watad, Julio Wainstein, Yosefa Bar-Dayan
BACKGROUND: Diabetes mellitus (DM) is a prevalent metabolic disease characterized by chronic hyperglycemia. A primary burden of DM is related to its long-term complications, which have been shown to impact the course of hospitalization and to influence patients' outcome. AIM: To assess the role of in-hospital glucose control on length of stay, 30-days and 1-year mortality. METHODS: This is a retrospective study that included patients admitted to the cardiac intensive care unit (CICU) of the Edith Wolfson Medical Centre between 01 January, 2010 and 31 December 2013...
January 11, 2019: Cardiovascular Diabetology
Federico Biscetti, Nicola Bonadia, Francesco Santini, Flavia Angelini, Elisabetta Nardella, Dario Pitocco, Angelo Santoliquido, Marco Filipponi, Raffaele Landolfi, Andrea Flex
BACKGROUND: Sortilin is a 95-kDa protein which has recently been linked to circulating cholesterol concentration and lifetime risk of developing significant atherosclerotic disease. Sortilin is found inside different cell types and circulating in blood. Higher circulating sortilin concentration has been found in patients with coronary atherosclerosis compared to control subjects. Sortilin concentration is influenced by statin therapy. METHODS: We enrolled statin-naïve subjects with type 2 diabetes mellitus and we performed a cross-sectional study to evaluate the association between sortilin levels and the presence of clinically significant lower limb peripheral artery disease (PAD) in a population of statin-free diabetic subjects...
January 11, 2019: Cardiovascular Diabetology
Richard E Gilbert, Kim A Connelly
No abstract text is available yet for this article.
January 11, 2019: Cardiovascular Diabetology
Claudia R L Cardoso, Guilherme C Salles, Nathalie C Leite, Gil F Salles
BACKGROUND: The prognostic importance of carotid atherosclerosis in individuals with diabetes is unsettled. We aimed to evaluate the relationships between parameters of carotid atherosclerosis and the future occurrence of micro- and cardiovascular complications in individuals with type 2 diabetes. METHODS: Ultrasonographic parameters of carotid atherosclerosis, intima-media thickness (CIMT) and plaques, were measured at baseline in 478 participants who were followed-up for a median of 10...
January 10, 2019: Cardiovascular Diabetology
Yingrui Li, Bin Liu, Yu Li, Xiaodong Jing, Songbai Deng, Yulin Yan, Qiang She
BACKGROUND: Epicardial fat tissue (EFT) is the visceral fat distributed along the coronary arteries between the pericardium and the myocardium. Increases in EFT are closely related to the occurrence of diabetes mellitus (DM) and cardiovascular disease. To further understand the link between EFT and DM, we conducted a meta-analysis of the relevant literature. METHODS: We systematically searched electronic databases for studies on EFT performed in DM patients and published up to 30 September 2018...
January 10, 2019: Cardiovascular Diabetology
Qutuba G Karwi, Liyan Zhang, Cory S Wagg, Wang Wang, Manoj Ghandi, Dung Thai, Hai Yan, John R Ussher, Gavin Y Oudit, Gary D Lopaschuk
BACKGROUND: In heart failure the myocardium becomes insulin resistant which negatively influences cardiac energy metabolism and function, while increasing cardiac insulin signalling improves cardiac function and prevents adverse remodelling in the failing heart. Glucagon's action on cardiac glucose and lipid homeostasis counteract that of insulin's action. We hypothesised that pharmacological antagonism of myocardial glucagon action, using a human monoclonal antibody (mAb A) against glucagon receptor (GCGR), a G-protein coupled receptor, will enhance insulin sensitivity and improve cardiac energy metabolism and function post myocardial infarction (MI)...
January 9, 2019: Cardiovascular Diabetology
Antonio E Pontiroli, Ahmed S Zakaria, Marco Fanchini, Chiara Osio, Elena Tagliabue, Giancarlo Micheletto, Alessandro Saibene, Franco Folli
BACKGROUND AND AIM: Several studies have shown that bariatric surgery reduces long term mortality compared to medical weight loss therapy. In a previous study we have demonstrated that gastric banding (LAGB) is associated with reduced mortality in patients with and without diabetes, and with reduced incidence of obesity co-morbidities (cardiovascular disease, diabetes, and cancer) at a 17 year follow-up. The aim of this study was to verify at a longer time interval (23 years) mortality and incidence of co-morbidities in patients undergoing LAGB or medical weight loss therapy...
December 29, 2018: Cardiovascular Diabetology
Xiaowei Zhang, Zhiwei Zhang, Yajuan Yang, Ya Suo, Ruimeng Liu, Jiuchun Qiu, Yungang Zhao, Ning Jiang, Changle Liu, Gary Tse, Guangping Li, Tong Liu
BACKGROUND: There are increasing evidence that left ventricle diastolic dysfunction is the initial functional alteration in the diabetic myocardium. In this study, we hypothesized that alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function and structure in diabetic rabbits. METHODS: A total of 30 rabbits were randomized into control group (CON, n = 10), alloxan-induced diabetic group (DM, n = 10) and alogliptin-treated (12...
December 27, 2018: Cardiovascular Diabetology
Celestino Sardu, Michelangela Barbieri, Maria Luisa Balestrieri, Mario Siniscalchi, Pasquale Paolisso, Paolo Calabrò, Fabio Minicucci, Giuseppe Signoriello, Michele Portoghese, Pasquale Mone, Davide D'Andrea, Felice Gragnano, Alessandro Bellis, Ciro Mauro, Giuseppe Paolisso, Maria Rosaria Rizzo, Raffaele Marfella
Following publication of the original article [1], the authors reported an error in Acknowledgment section. The last sentence should read as "All authors have read and approval the submission to Cardiovascular Diabetology.
December 27, 2018: Cardiovascular Diabetology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"